JP6122042B2 - ロフルミラストの製造方法 - Google Patents
ロフルミラストの製造方法 Download PDFInfo
- Publication number
- JP6122042B2 JP6122042B2 JP2014560237A JP2014560237A JP6122042B2 JP 6122042 B2 JP6122042 B2 JP 6122042B2 JP 2014560237 A JP2014560237 A JP 2014560237A JP 2014560237 A JP2014560237 A JP 2014560237A JP 6122042 B2 JP6122042 B2 JP 6122042B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title description 21
- 229960002586 roflumilast Drugs 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 238000005580 one pot reaction Methods 0.000 claims description 15
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims description 14
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 9
- -1 nickel peroxide Chemical class 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 9
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 229910001919 chlorite Inorganic materials 0.000 claims description 7
- 229910052619 chlorite group Inorganic materials 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 239000002841 Lewis acid Substances 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 150000007517 lewis acids Chemical group 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 4
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 3
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 claims description 2
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 229940069078 citric acid / sodium citrate Drugs 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002952 polymeric resin Substances 0.000 claims description 2
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 2
- 229960002218 sodium chlorite Drugs 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 229920003002 synthetic resin Polymers 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 229940077239 chlorous acid Drugs 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 description 13
- 150000003936 benzamides Chemical class 0.000 description 13
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 229940054066 benzamide antipsychotics Drugs 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 7
- WFWCXZPAPUKWOC-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(Cl)C=NC=C1Cl WFWCXZPAPUKWOC-UHFFFAOYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- ISIQAMHROGZHOV-UHFFFAOYSA-N 3,5-dichloropyridin-4-amine Chemical compound NC1=C(Cl)C=NC=C1Cl ISIQAMHROGZHOV-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- GDEHIRHIBWKMCY-UHFFFAOYSA-N 1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-n-(3,5-dichloropyridin-4-yl)methanimine Chemical compound C1=C(OCC2CC2)C(OC(F)F)=CC=C1C=NC1=C(Cl)C=NC=C1Cl GDEHIRHIBWKMCY-UHFFFAOYSA-N 0.000 description 5
- 150000002466 imines Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000003927 aminopyridines Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 150000003935 benzaldehydes Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 0 *c(ccc(C(Nc(c(Cl)cnc1)c1Cl)=O)c1)c1O Chemical compound *c(ccc(C(Nc(c(Cl)cnc1)c1Cl)=O)c1)c1O 0.000 description 3
- AHVVCELVGCPYGI-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1OCC1CC1 AHVVCELVGCPYGI-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- IGFDIFLMMLWKKY-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid Chemical class OC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 IGFDIFLMMLWKKY-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000003236 benzoyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000006315 carbonylation Effects 0.000 description 2
- 238000005810 carbonylation reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 150000004252 dithioacetals Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 150000004250 monothioacetals Chemical class 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- FHWQHMNXGCGXRJ-UHFFFAOYSA-N FC(Oc(ccc(CCCNc(c(Cl)cnc1)c1Cl)c1)c1OCC1CC1)F Chemical compound FC(Oc(ccc(CCCNc(c(Cl)cnc1)c1Cl)c1)c1OCC1CC1)F FHWQHMNXGCGXRJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
- C07C43/2055—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/307—Compounds having groups having acetal carbon atoms bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本願は、2012年3月7日に出願された国際出願番号PCT/CN2012/072020に基づく優先権を主張し、そしてその内容は本明細書に参照により組み込まれる。
適用なし
適用なし
ある態様において、本発明は、式VIcの化合物:
この方法は、以下のステップ:
a)式IIcの化合物:
b)式Vcの化合物を、式VIcの化合物を提供するために適した条件下で酸化すること
を含み、
ここで、R1及びR2は、独立して、H;C1-6アルキル;C3-7シクロアルキル;C3-7シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択される、を含む。
「交差した(crossed)」イミン結合はシス異性体、トランス異性体、又はシス異性体とトランス異性体との混合物を示す]
並びに、式IIIcの化合物:
R1及びR2は、独立して、H;C1-6アルキル;C3-7シクロアルキル;C3-7シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択され、
R4及びR5は、独立して、C1-6アルキル及びアシルからなる群から選択され、又は
R4及びR5は、一緒になって、場合により置換された5〜7員環を形成する]
を提供する。
I.総論
本発明は、置換ベンズアルデヒドからの置換ベンズアミドの調製方法を提供する。このワンポット法は、穏和で、安全で、経済効率的で、環境に優しいことがわかっている。本発明の方法は、塩化チオニルや水素化ナトリウムなどの腐食性で危険な試薬の必要性を排除している。
本明細書において用語「接触させる (contacting)」は、反応することができる少なくとも2つの異なる分子種を接触させるプロセスを指す。しかし、生じる反応生成物は、添加された試薬間の反応から直接製造することができるか、又は反応混合物中で製造することができる1種又はそれ以上の添加された試薬からの中間体から製造することができることを、理解されたい。
本発明は、置換ベンズアルデヒドからの置換ベンズアミドの製造方法を提供する。ある態様において本発明は、式VIcの化合物:
この方法は、
a)式IIcの化合物:
b)式Vcの化合物を、式VIcの化合物を提供するために適した条件下で酸化すること
を含み、
ここで、R1及びR2は、独立して、H;C1-6アルキル;C3-7シクロアルキル;C3-7シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択される。
i)式(IIIc)の化合物:
ii)式Vcの化合物を形成するために適した条件下で、式IIIcの化合物に式IVaの化合物:
ここで、
R4及びR5は、独立して、C1-6アルキル及びアシルからなる群から選択されるか、又は
R4及びR5は、一緒になって、場合により置換された5〜7員環を形成する。
a)式IIbの化合物をワンポット反応で、式IIIbの化合物:
b)式IIIbの化合物に式IVaの化合物:
c)式Vbの化合物を酸化して、式VIbの化合物を提供すること、を含む。
ここで、R1及びR2は、独立して、H;C1-6アルキル;C3-7シクロアルキル;C3-7シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択される、化合物を提供する。
ここで、
R1及びR2は、独立して、H;C1-6アルキル;C3-7シクロアルキル;C3-7シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択され、
R4及びR5は、独立して、C1-6アルキル及びアシルからなる群から選択され、又は
R4及びR5は、一緒になって、場合により置換された5〜7員環を形成する、化合物を提供する。
以下の例は、本発明をさらに詳細に説明するために提示される。しかし本発明は、決して本明細書に記載された具体例に限定されるものではない。
3,5−ジクロロ−N−(3,4−ジメトキシ)ベンジリデン)ピリジン−4−アミン(Va)の合成
トルエン中の3,4−ジメトキシベンズアルデヒド(5g,30ミリモル,1.2当量)の溶液(25mL)に、PTSA(103mg,0.6ミリモル,0.02当量)とTMOF(3.6mL,33ミリモル,1.32当量)を加えた。反応混合物を2時間加熱還流し、次に65±5℃に冷却した。4−アミノ−3,5−ジクロロピリジン(4.1g,25ミリモル,1.0当量)と追加のPTSA(413mg,2ミリモル,0.08当量)を添加し、次に反応混合物を120℃に加熱し、15時間還流させた。混合物を室温まで冷却し、n−ヘプタン(40mL)を添加した。沈殿物を濾過し、粗生成物をDCM/n−ヘプタンから再結晶化して、2.8gのイミンを無色の固体として得た。1H NMR (300 MHz, CDCl3) δ 8.47 (s, 2H), 8.23 (s, 1H), 7.64 (s, 1H), 7.38 (d, 1H, J = 8.4 Hz), 6.98 (d, 1H, J = 8.4 Hz), 3.99 (s, 3H), 3.98 (s, 3H)。
N−(3,5−ジクロロ−ピリジン−4−イル)−3,4−ジメトキシ−ベンズアミド(VIa)の合成
実施例1のイミンVa(311mg,1.0ミリモル,1.0当量)を、THF(5mL)と2−メチルブト−2−エン(1.1mL,10.0ミリモル,10.0当量)の混合物に溶解した。この溶液に、NaClO2(452mg、5.0ミリモル,5.0当量)を加えた。NaH2PO4の水溶液(3.3M,1.5mL,5.0ミリモル,5.0当量)を滴下して加えながら、反応混合物を激しく撹拌した。TLCにより反応が完了したことを確認後、反応混合物をDCM(30mL)で希釈し、水、10%Na2S2O3水溶液と食塩水(各10mL)で洗浄した。有機層をMgSO4上で乾燥し、溶媒を蒸発させて粗ベンズアミド(283mg)を得た。1H NMR (300 MHz, CDCl3) δ 8.57 (s, 2H), 7.69 (s, 1H), 7.54-7.52 (m, 3H), 6.97 (d, 1H, J = 9.0 Hz), 6.97 (s, 6H)。
3,5−ジクロロ−N−(3−(シクロプロピルメトキシ)−4−(ジフルオロメトキシ)ベンジリデン)ピリジン−4−アミン(Vb)の合成
20〜30℃で、N2雰囲気下でトルエン中のIIb(30g,123.9ミリモル,1.0当量)の溶液(150mL)に、オルトギ酸トリメチル(TMOF,46.0g,433.7ミリモル,3.5当量)とアンバーリスト15ウェット(9.0g,30%w/w)を加えた。次に混合物を加熱還流し、反応が完了するまで還流を続けた。溶媒及び過剰のTMOFを減圧下で50〜60℃で除去して、IIIbを得た。この混合物にトルエン(150mL)を添加し、次に、IVa(21.2g,130.1ミリモル,1.05当量)とTFA(2.8g,24.8ミリモル,0.2当量)を40〜50℃の温度で加えた。フラスコに冷却器及び受容器を接続し、混合物を再度110℃に加熱し、反応が完了するまで蒸留を続けた。混合物を50〜60℃に冷却し、次に濾過し、固体をトルエン(30mL)で洗浄した。濾液を、それぞれ飽和NaHCO3(60mL)と水(60mL)で洗浄した。有機相を減圧下(30〜50mmHg)で除去した。フラスコに95%EtOH(150mL)を、次に溶媒75mLを投入し、減圧下で50℃で蒸留した。再度、残渣に75mLの95%EtOHを投入し、次に溶媒75mLを蒸留してVbのEtOH溶液を得た。混合物を25℃に冷却し、次に追加の95%EtOHを投入して210mLとし、次に同じ温度でH2O(90mL)を投入した。懸濁した溶液を30分間撹拌し、次に0〜5℃に冷却し、1時間撹拌した。スラリーを濾過し、フィルターケーキをH2O(30mL)で洗浄し、減圧下で、40℃で2時間乾燥してVb(35g,73%収率)を得た。
MS m/z (M+1): 387.1;
IR (KBr): 3000, 2940, 1635, 1550, 1270, 1550 -1cm.
1H NMR (300 MHz, CDCl3) δ 8.43 (s, 2H), 8.26 (s, 1H), 7.68 (s, 1H), 7.39-7.26 (m, 2H), 7.00-6.51 (t, 1H, J = 75 Hz), 4.00 (d, 2H, J = 6.9 Hz), 1.33 (m, 1H), 0.71-0.65 (m, 2H), 0.42-0.38 (m, 2H).
13C NMR (125 MHz, CDCl3) δ 165.38, 153.31, 150.98, 147.85, 144.15, 132.78, 124.23, 122.99, 122.29, 117.81 (CF2, JCF = 260 Hz), 115.74 (CF2), 113.66 (CF2), 112.51, 74.01, 9.99, 3.22.
19F NMR (282 MHz, CDCl3) δ -82.24, -82.51。
3−(シクロプロピルメトキシ)−N−(3,5−ジクロロ−ピリジン−4−イル)−4−(ジフルオロメトキシ)ベンズアミド(VIb;ロフルミラスト)の合成
Vb(24g,62.0ミリモル,1.0当量)をCH3CN(96mL)と2−メチル−2−ブテン(17.5g,248.2ミリモル,4.0当量)の混合物に溶解した。次に、25%NaClO2水溶液[84mLのH2O(4.0当量)中28.0g(80%固体、249ミリモル)]を一度に加えた。混合物を氷水浴に入れた。CH3COOH水溶液[H2Oで希釈したCH3COOH(11.2g,186ミリモル)(48mL、3.0当量)]を加え、温度を25℃未満に維持した。反応が進行するにつれて生成物がゆっくり沈殿する間、反応混合物を20〜30℃で激しく撹拌した。反応物を2時間撹拌し、96mLのH2Oを加え、撹拌を1時間続けた。得られたスラリーを濾過し、フィルターケーキをH2O(36mL)で洗浄した。生成物を減圧下で、40℃で3時間乾燥させて、粗VIb、ロフルミラスト(22.4g,98.0%の純度で92.4%の収率)を得た。
粗ロフルミラスト(10g,24.8ミリモル)とCH3CN(45mL)を、250mLの反応器に入れた。混合物を撹拌し、65℃に加熱して材料を溶解した。不溶性材料を熱濾過によって除去した。混合物を70°Cに加熱し、次に、同じ温度でH2O(22.3mL)を溶液に添加し、次に68±2℃に冷却し、2時間その温度で保持した。混合物を25±3℃に冷却し、この温度で12時間連続して撹拌した。得られた結晶を濾過により回収し、フィルターケーキをH2O(10mL)で洗浄し、40±2°Cで、減圧下で4時間乾燥して、ロフルミラスト(8.2g,99.7%の純度で収率82%)を得た。
MS m/z (M+1): 403.0
IR (KBr): 3445, 3262, 1651, 1503, 1156 -1cm.
1H NMR (300 MHz, CDCl3) δ 8.58 (s, 2H), 7.66 (s, 1H), 7.59 (d, 1H, J = 2.1 Hz), 7.49 (dd, 1H, J = 2.1, 8.4 Hz), 7.31 (d, 1H, J = 8.4 Hz), 7.00-6.50 (t, 1H, J = 74.7 Hz), 3.98 (d, 2H, J = 6.9), 1.4-1.2 (m, 1H), 0.70-0.67 (m, 2H), 0.39-0.37 (m, 2H).
13C NMR (125 MHz, CDCl3) δ 163.70, 150.99, 148.38, 143.94, 139.70, 130.88, 128.91, 122.36, 119.93, 117.76 (CF2, JCF = 261 Hz), 115.68 (CF2), 114.32, 113.66 (CF2), 74.26, 10.02, 3.29.
19F NMR (282 MHz, CDCl3) δ -82.35, -82.62。
アセタール中間体を介さないN−(3,5−ジクロロ−ピリジン−4−イル)−3,4−ジメトキシ−ベンズアミド(Va)の合成
トルエン中の3,4−ジメトキシベンズアルデヒド(5g,30ミリモル,1.2当量)の溶液(25mL)に、PTSA(103mg,0.6ミリモル,0.02当量)と4−アミノ−3,5−ジクロロピリジン(4.1g,25ミリモル,1.00当量)を加えた。反応混合物を30日間加熱還流した。混合物を室温まで冷却し、n−ヘプタン(40mL)を添加した。沈殿物を濾過し、粗生成物をDCM/n−ヘプタンから再結晶化して、2.24gのイミンを無色の固体として得た。1H NMR (300 MHz, CDCl3) δ 8.47 (s, 2H), 8.23 (s, 1H), 7.64 (s, 1H), 7.38 (d, 1H, J = 8.4 Hz), 6.98 (d, 1H, J = 8.4 Hz), 3.99 (s, 3H), 3.98 (s, 3H)。
アセタール中間体の無い3,5−ジクロロ−N−(3−(シクロプロピルメトキシ)−4−(ジフルオロメトキシ)ベンジリデン)ピリジン−4−アミン(Vb)の合成
異なる酸化条件を使用するN−(3,5−ジクロロ−ピリジン−4−イル)−3,4−ジメトキシ−ベンズアミド(VIa)の合成
実施形態から明らかなように、式Vaの化合物の式VIaの化合物への酸化は、種々の酸化剤を用いて行うことができる。表3は、KMnO4、m−CPBA、オキソン及びTBHPを使用した結果を示す。変換の割合はHPLCで観察される。反応は通常の条件下で、1〜2当量の酸化剤の存在下で行われる。反応時間は1〜24時間である。
異なる酸化条件を使用する3−(シクロプロピルメトキシ)−N−(3,5−ジクロロ−ピリジン−4−イル)−4−(ジフルオロメトキシ)ベンズアミド(VIb)
実施形態から明らかなように、式Vbの化合物の式VIbの化合物への酸化は、種々の酸化剤を用いて行うことができる。表4は、KMnO4、m−CPBA、オキソン及びTBHPを使用した結果を示す。変換の割合は、HPLCにより観察される。反応は通常の酸化条件下で、1〜2当量の酸化剤の存在下で行われる。反応時間は1〜24時間である。
Claims (16)
- 式VIcの化合物:
a)式IIcの化合物:
b)式IIIcの化合物を、式IVaの化合物:
を提供し;
c)式Vcの化合物を酸化して、式VIcの化合物を提供すること
を含み、
ここで、ステップa)及びb)は酸の存在下、無極性有機溶媒中で、ワンポット反応で行われ、
R1及びR2は、独立して、H;C1-6アルキル;C3-7シクロアルキル;C3-7シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択され、
R 4 及びR 5 は、独立して、C 1-6 アルキル及びアシルからなる群から選択されるか;又は、
R 4 及びR 5 は、一緒になって、場合により置換された5〜7員環を形成する、前記製造方法。 - 前記無極性有機溶媒が、トルエン及びキシレンからなる群から選択される、請求項1に記載の製造方法。
- 前記酸が、p−トルエンスルホン酸、カンファースルホン酸、ポリマー樹脂系ベースのスルホン酸及び酢酸からなる群から選択される、請求項1に記載の製造方法。
- 前記アルデヒド保護試薬が、オルトギ酸トリメチル、オルトギ酸トリエチル、オルト酢酸トリエチル、オルト酢酸トリメチル、無水酢酸及びエチレングリコールからなる群から選択される、請求項1に記載の製造方法。
- ステップc)が、クロライト、遷移金属触媒、過酸化ニッケル、m−CPBA、TBHP、ペルオキソ一硫酸カリウム、およびそれらの混合物からなる群から選択される、請求項1に記載の製造方法。
- 前記クロライトが、亜塩素酸、亜塩素酸マグネシウム、亜塩素酸ナトリウム及び亜塩素酸カリウムからなる群から選択される、請求項5に記載の製造方法。
- 前記クロライトが、HCl/クエン酸ナトリウム、クエン酸/クエン酸ナトリウム、酢酸/クエン酸ナトリウム、リン酸二水素カリウム、リン酸水素二カリウム/リン酸二水素ナトリウム、酢酸及び2ナトリウムリン酸塩からなる群から選択される電解質で緩衝化される、請求項5に記載の製造方法。
- R1及びR2は、独立して、C3-7シクロアルキルメチル及び、フッ素で部分的に又は完全に置換されるC1-4アルキルからなる群から選択される、請求項9に記載の化合物。
- 式VIc:
a)式IIc:
の化合物を形成し、
b)式Vcの化合物を酸化して、式VIcの化合物を提供すること
を含み、
ここで、R 1 及びR 2 は、独立して、H;C 1-6 アルキル;C 3-7 シクロアルキル;C 3-7 シクロアルキルメチル;及び、フッ素で部分的に又は完全に置換されるC 1-4 アルキルからなる群から選択される、製造方法。 - 前記触媒がルイス酸である、請求項12に記載の製造方法。
- 前記ルイス酸が、TMSOTf、TMSCl、PTSA、TfOH、MSA、TFA及びそれらの混合物からなる群から選択される、請求項13に記載の製造方法。
- 前記反応促進剤がシリル化剤である、請求項12に記載の製造方法。
- 前記シリル化剤が、BSA、BSTFA及びそれらの混合物からなる群から選択される、請求項15に記載の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2012/072020 | 2012-03-07 | ||
PCT/CN2012/072020 WO2013131255A1 (en) | 2012-03-07 | 2012-03-07 | Preparation method of roflumilast |
PCT/CN2013/072286 WO2013131484A1 (en) | 2012-03-07 | 2013-03-07 | Process for preparation of roflumilast |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015510869A JP2015510869A (ja) | 2015-04-13 |
JP6122042B2 true JP6122042B2 (ja) | 2017-04-26 |
Family
ID=49115870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014560237A Active JP6122042B2 (ja) | 2012-03-07 | 2013-03-07 | ロフルミラストの製造方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US9085533B2 (ja) |
EP (1) | EP2822929B1 (ja) |
JP (1) | JP6122042B2 (ja) |
KR (1) | KR101680182B1 (ja) |
AU (1) | AU2013230356B2 (ja) |
BR (1) | BR112014022074A2 (ja) |
CA (1) | CA2865539C (ja) |
ES (1) | ES2640470T3 (ja) |
IL (1) | IL234366A (ja) |
IN (1) | IN2014DN07325A (ja) |
NZ (1) | NZ629161A (ja) |
TW (1) | TWI460163B (ja) |
WO (2) | WO2013131255A1 (ja) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2114114C (en) | 1992-06-15 | 2005-05-03 | Nigel Robert Arnold Beeley | Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors |
ATE282025T1 (de) | 1992-07-28 | 2004-11-15 | Aventis Pharma Ltd | Inhibitoren von c-amp phosphodiesterase |
AU687087B2 (en) | 1993-07-02 | 1998-02-19 | Takeda Gmbh | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
JPH07316054A (ja) * | 1993-09-06 | 1995-12-05 | Ishihara Sangyo Kaisha Ltd | ピリダジノン誘導体またはその塩、それらの製造方法およびそれらを含有する抗ショック剤 |
AU2001261962B2 (en) | 2000-05-25 | 2005-04-21 | Merck Frosst Canada Ltd | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
JP4182218B2 (ja) * | 2001-05-30 | 2008-11-19 | 学校法人東京理科大学 | アポトーシスを誘導する新規なグルコース誘導体、その製造方法及び医薬としてのその用途 |
US6822114B1 (en) | 2002-10-08 | 2004-11-23 | Albemarle Corporation | Process for production of fluoroalkoxy-substituted benzamides and their intermediates |
CA2503290C (en) * | 2003-03-10 | 2012-12-04 | Altana Pharma Ag | Novel process for the preparation of roflumilast |
BRPI0415753A (pt) * | 2003-10-21 | 2006-12-19 | Pharmacia Corp | método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm |
JP4996834B2 (ja) * | 2005-07-06 | 2012-08-08 | 高砂香料工業株式会社 | バニリンアセタール類およびそれを含有する感覚刺激剤組成物 |
DE602007012105D1 (de) | 2006-07-14 | 2011-03-03 | Chiesi Farma Spa | Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
CN102336703B (zh) * | 2011-07-20 | 2013-09-25 | 华润赛科药业有限责任公司 | 一种制备罗氟司特的方法 |
CN102351787B (zh) * | 2011-08-18 | 2014-08-13 | 天津市汉康医药生物技术有限公司 | 高生物利用度的罗氟司特化合物 |
-
2012
- 2012-03-07 WO PCT/CN2012/072020 patent/WO2013131255A1/en active Application Filing
-
2013
- 2013-03-07 CA CA2865539A patent/CA2865539C/en active Active
- 2013-03-07 US US14/382,967 patent/US9085533B2/en active Active
- 2013-03-07 KR KR1020147028243A patent/KR101680182B1/ko active IP Right Grant
- 2013-03-07 EP EP13757220.2A patent/EP2822929B1/en active Active
- 2013-03-07 BR BR112014022074A patent/BR112014022074A2/pt not_active IP Right Cessation
- 2013-03-07 JP JP2014560237A patent/JP6122042B2/ja active Active
- 2013-03-07 WO PCT/CN2013/072286 patent/WO2013131484A1/en active Application Filing
- 2013-03-07 IN IN7325DEN2014 patent/IN2014DN07325A/en unknown
- 2013-03-07 AU AU2013230356A patent/AU2013230356B2/en not_active Ceased
- 2013-03-07 ES ES13757220.2T patent/ES2640470T3/es active Active
- 2013-03-07 NZ NZ629161A patent/NZ629161A/en not_active IP Right Cessation
- 2013-03-07 TW TW102108114A patent/TWI460163B/zh active
-
2014
- 2014-08-28 IL IL234366A patent/IL234366A/en active IP Right Grant
-
2015
- 2015-06-10 US US14/736,062 patent/US9233925B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112014022074A2 (pt) | 2018-05-22 |
AU2013230356B2 (en) | 2016-12-22 |
CA2865539C (en) | 2016-08-23 |
IN2014DN07325A (ja) | 2015-04-24 |
US20150274667A1 (en) | 2015-10-01 |
EP2822929A4 (en) | 2016-01-13 |
ES2640470T3 (es) | 2017-11-03 |
IL234366A (en) | 2016-12-29 |
WO2013131255A1 (en) | 2013-09-12 |
EP2822929A1 (en) | 2015-01-14 |
WO2013131484A1 (en) | 2013-09-12 |
US9085533B2 (en) | 2015-07-21 |
TWI460163B (zh) | 2014-11-11 |
TW201341362A (zh) | 2013-10-16 |
AU2013230356A1 (en) | 2014-09-25 |
CA2865539A1 (en) | 2013-09-12 |
US20150025246A1 (en) | 2015-01-22 |
EP2822929B1 (en) | 2017-06-14 |
JP2015510869A (ja) | 2015-04-13 |
KR101680182B1 (ko) | 2016-11-28 |
KR20140138879A (ko) | 2014-12-04 |
US9233925B2 (en) | 2016-01-12 |
NZ629161A (en) | 2015-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2670751E (pt) | Métodos de fabrico de um composto profármaco inibidor da fixação do vih e intermediários | |
US6080876A (en) | Process for making phenyl heterocycles useful as COX-2 inhibitors | |
KR101728443B1 (ko) | 2-아미노니코틴산벤질에스테르 유도체의 제조 방법 | |
JP6122042B2 (ja) | ロフルミラストの製造方法 | |
CN104245672B (zh) | 制备罗氟司特的方法 | |
JP5205971B2 (ja) | テトラヒドロピラン化合物の製造方法 | |
TWI542578B (zh) | Preparation of Benzyl Nicotinic Acid Benzyl Ester Derivatives | |
JPH0525876B2 (ja) | ||
KR100502833B1 (ko) | 심바스타틴 및 이의 중간체 화합물들의 개선된 제조방법 | |
JP3646225B2 (ja) | 芳香族エステル誘導体及びその中間体並びにそれらの製造方法 | |
JPS5916878A (ja) | 2,4−ジヒドロキシ−3−アセチルキノリン類の製造方法 | |
JP2024509535A (ja) | 4-オキソテトラヒドロフラン-2-カルボン酸アルキルの調製方法 | |
JP5631741B2 (ja) | ピラジン誘導体類の製造方法及びその中間体類 | |
WO2011065351A1 (ja) | シクロヘキサン誘導体の製造方法 | |
JPH0219832B2 (ja) | ||
JPH0128013B2 (ja) | ||
JPS6059231B2 (ja) | ピルブテロ−ルおよび同族体の製造のための中間体 | |
JPS61221153A (ja) | 2−ヒドロキシ−3−ブテン酸エステル誘導体の製造方法 | |
JP2002053552A (ja) | 4,6−ジメチルインドール及びその誘導体の製造方法 | |
JPH0572379B2 (ja) | ||
JPH07165707A (ja) | 5−アミノ−3,4−ジヒドロ−1−オキシド−2h−ピロール類およびその中間体 | |
JPS60181049A (ja) | 菊酸誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160119 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170330 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6122042 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |